System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Serigne N Lo, PhD is an expert in Oncology at University of Sydney (Australia). As of October 2026, ScienceLeadR ranks Serigne N Lo in the top 1% of experts worldwide for Melanoma and Skin Neoplasms. Serigne N Lo has authored 396 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 2 of them ongoing. SLR score: 1,439 (community average: 125). How the SLR is computed.

LeadR Profile

Serigne N Lo, PhD University of Sydney Australia
1 439 ScienceLeadR Reputation 1439

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology - Surgery - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2012 - 2026
Source: PubMed

University of New England (Australia)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 396

Citations

Citations: 13 450 1st author: 19 Last author: 29 Unique author: 2

Main journals

J Clin Oncol 47
Eur J Cancer 25
Ann Surg Oncol 19
Br J Dermatol 18
Ann Oncol 17

Best Journals

J Clin Oncol 36
Ann Oncol 14
Lancet Oncol 9

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Data-Driven Approach to Estimate Ambient Ammonia Concentrations.
PMID 42933757 — research design, machine learning, deep learning, environmental health		Environ Res20260
Psychosocial mediators for the impact of personal genomic risk information on melanoma prevention and early detection behaviors.
PMID 42847397 — skin, melanoma, mediation analysis		Ann Behav Med20260
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
PMID 42823486 — cells, molecular biology, melanoma, neoplasm metastasis, neoadjuvant therapy, therapeutics		Nat Med Top journal20260
On a Penalized Likelihood Approach for Joint Modeling of Longitudinal Covariates and Partly Interval-Censored Data-An Application to the Anti-PD1 Brain Collaboration Trial.
PMID 42730497 — brain, survival analysis		Biom J20260
Investigating the repurposing potential of immune checkpoint inhibition for cancer treatment using Mendelian randomisation.
PMID 42620263 — mortality, lung, ovary, neoplasms, therapeutics, plasma		Res Sq20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 4
N/A 3
Phase 3 2
Phase 4 2

By status:

Completed 6
Active not recruiting 3
Recruiting 1
Unknown 1

By type:

Interventional 11

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 2
multicentric5to9 2
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
NCT06767306 — radiotherapy, cells, quality of life, radiosurgery, melanoma, biomarkers, immunotherapy, immune checkpoint inhibitors, research, beds, therapeutics, names		Phase 2Recruiting2025
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
NCT04949113 — lymph nodes, melanoma, immunotherapy, neoplasm metastasis, lymph, nivolumab, ipilimumab, dissection		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS